Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase NA 5Phase 1/2 3Phase 2/3 1

Status

Unknown 2Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 6Endocrine 6

Conditions

Neuroendocrine Tumors 169Carcinoma, Neuroendocrine 73Thyroid Neoplasms 52Pheochromocytoma 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Adrenocortical Carcinoma 40Carcinoid Tumor 39Paraganglioma 35Adenocarcinoma, Follicular 33Neoplasm Metastasis 29Neoplasms 28Somatostatinoma 26Adenoma, Islet Cell 26Insulinoma 22Carcinoma, Medullary 22Carcinoma, Islet Cell 22Pancreatic Neoplasms 21Pituitary Neoplasms 20Sarcoma 19Glucagonoma 19Gastrinoma 19Gastro-enteropancreatic neuroendocrine tumor 16Head and Neck Neoplasms 15Colorectal Neoplasms 14Multiple Endocrine Neoplasia Type 1 13Neuroblastoma 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Vipoma 11

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1donafenib 1Thyrotropin Alfa 1Sorafenib 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Differentiated Thyroid Cancer × Endocrine × Clear all
NCT05852223 2026-04-20

NePenThe

Istituti Clinici Scientifici Maugeri SpA

Phase 2 Recruiting
25 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Massachusetts Eye and Ear Infirmary

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown
120 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT05989425 2023-08-14

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Fudan University

Phase 2 Recruiting
32 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01263951 2021-10-26

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Thomas Jefferson University

Phase 2 Unknown
35 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡